Not yet independently audited
This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.
Guideline registry — degenerative disc disease and low-back pain¶
Last checked: 2026-10-28 (targeted update; older row-specific access dates remain explicit)
Scope¶
A live PubMed E-utilities title search on 2026-08-30 returned ten DDD-linked guideline records, all addressing a procedure, pain phenotype, herniation or fusion selection rather than imaging-defined DDD as one uniform condition. This registry therefore includes low-back-pain, radicular, surgical, occupational and regenerative guidance that governs how the label is used. Status reflects the issuing body’s site on the access date, not a legal determination.
Master table¶
| Body | Year | Region | Scope | Citation / live source | Status |
|---|---|---|---|---|---|
| Acute Low Back Pain Guideline Project / AAPM collaborators | 2026 | United States | Acute outpatient LBP <6 weeks, with/without radiculopathy | Skelly et al., PMID 42687437; publisher, accessed 2026-09-30; AAPM clinician page, accessed 2026-10-14 | Published; AAPM key-recommendation summary now live (2026-10-14); full-guideline grades not extracted |
| Chinese Society for the Study of the Lumbar Spine / Chinese Association of Spine | 2026 | China | Multidisciplinary LBP consensus by etiology, explicitly including discogenic LBP | Gao et al., PMID 42660880; open-access full text PMC13522480 | Published 2026-08-27; new; recommendation wording verified from full text 2026-10-14 |
| World Health Organization | 2023 | Global | Nonsurgical chronic primary low-back pain in primary/community care | WHO publication, accessed 2026-08-30 | current |
| NICE | 2016; update 2026 | England/Wales | Low-back pain and sciatica, age ≥16 | NG59 recommendations; update information, accessed 2026-10-14 | current; last updated 29 July 2026 (psychological-therapy recommendations withdrawn) |
| VA/DoD | 2022 | United States | Diagnosis and treatment of low-back pain | VA/DoD guideline hub, accessed 2026-08-30 | 2022 guideline remains listed on the official hub; replacement timing not established on 2026-10-21 |
| North American Spine Society | 2021 | North America | Diagnosis and treatment of adult low-back pain | NASS guideline, accessed 2026-08-30 | current listed document |
| Australian Commission on Safety and Quality in Health Care | 2022 | Australia | New acute low-back-pain episode: assessment, management, review/referral | Clinical Care Standard, accessed 2026-08-30 | current; page updated 2026 |
| American College of Occupational and Environmental Medicine | 2020 | United States | Working-age low-back disorders; non/minimally invasive care | ACOEM summary guideline, accessed 2026-08-30 | current document; update cycle due/unclear |
| Belgian Health Care Knowledge Centre (KCE) | 2017 | Belgium | Low-back and radicular pain | KCE Report 287A, accessed 2026-08-30 | aging; update project planned 2026 |
| Danish Health Authority | 2016 | Denmark | Recent-onset low-back pain | English quick guide, accessed 2026-08-30 | historical/current status unclear |
| German AWMF/NVL | 2017 | Germany | Nonspecific low-back pain | NVL Kreuzschmerz v2, accessed 2026-08-30 | expired 2021 |
| American College of Physicians | 2017 | United States | Noninvasive acute, subacute and chronic nonradicular low-back pain | Qaseem et al., PMID 28192789; ACP source, accessed 2026-08-30 | ACP lists inactive; partially updates 2007 |
| ACP/American Pain Society | 2007 | United States | Diagnosis/treatment of low-back pain | ACP inactive-guideline registry, accessed 2026-08-30 | superseded in part → ACP 2017; inactive |
| North American Spine Society | 2012 | North America | Lumbar disc herniation with radiculopathy | NASS clinical-guideline registry, accessed 2026-08-30 | older; remains listed |
| American Society of Interventional Pain Physicians | 2019 | United States/international | Responsible use of biologics for low-back pain | Navani et al., PMID 30717500; ASIPP source, accessed 2026-08-30 | superseded/updated → ASIPP 2025 |
| American Society of Interventional Pain Physicians | 2025 | United States/international | Regenerative therapies for chronic low-back pain | Manchikanti et al., PMID 41481869; ASIPP source, accessed 2026-08-30 | current update |
| American Society of Pain and Neuroscience | 2022 | United States/international | Interventional treatments for low-back pain | Sayed et al., PMID 36510616 | published guideline; 2026-08-30 PubMed sweep found no later society-wide replacement |
| AANS/CNS Joint Section | 2014 | United States | Fusion procedures for lumbar degenerative disease: injection selection and economic assessment | Watters et al., PMID 24980590; Kaiser et al., PMID 24980580 | historical update; current supersession status unclear |
| Belgian KCE care pathway | 2017 | Belgium | Multidisciplinary low-back/radicular care pathway | KCE Report 295B, accessed 2026-08-30 | KCE warns guideline may be obsolete after 5 years |
2026-10-28 targeted check¶
Official pages retrieved 2026-10-28: NICE update information (HTTP 200; still last updated 29 July 2026), VA/DoD hub (HTTP 200; 2022 CPG still listed, page last updated 14 November 2025), NASS LBP guideline (HTTP 200; 2021 document still listed; the "2026 Biologic Interventions for Spinal Pathologies" item is a 13 November Nashville course, not a CPG), KCE planned projects (HTTP 200; study 2026-13 still planned, not published), AAPM clinician page (HTTP 200; summary still live; Skelly full text still publisher HTTP 403), WHO 2023 publication (HTTP 200). No replacement guideline was found on those named pages.
A PLoS Medicine systematic review of cost-effectiveness for guideline-recommended nonspecific-LBP interventions (Mathieson 2026, PMID 42945153) is an economic evidence synthesis, not a clinical practice guideline, and is catalogued here only as a companion to the existing 19 treatment/policy documents. Full text verified from the publisher manuscript. Crossref updated-by empty.
PubMed returned no published erratum to the 2026 Chinese multidisciplinary consensus in this window.
2026-10-21 targeted check and reporting standard¶
NICE’s update page still lists 29 July 2026; no later entry was found there. The VA/DoD hub still lists its 2022 document, and NASS lists its 2021 LBP guideline. KCE explicitly lists study 2026-13, an LBP-guideline update, under planned projects; this is not a published replacement. The AAPM clinician summary remains available, but the full Skelly guideline was still inaccessible through the publisher (HTTP 403), so recommendation-grade extraction remains pending.
| Issuing community | Document | Scope and status |
|---|---|---|
| ISSLS VERTEBRA Working Group | Schol et al. 2026, PMID 42900386; doi:10.1007/s00586-026-10373-w | Reporting standard for disc-regeneration trials, verified from publisher full text. Complements generic reporting standards; not a clinical practice guideline. Catalogue separately from the 19 treatment/policy documents. |
Sources retrieved 2026-10-21: NICE update information, VA/DoD hub, NASS registry, KCE planned/ongoing projects, AAPM clinician resources. These are checks of the named pages, not a worldwide absence of newer guidance.
2026-09-30 sweep¶
| Document/update | Verified scope and contribution | Status and limit |
|---|---|---|
| Acute Low Back Pain Guideline Project / AAPM collaborators, 2026; United States | Outpatient acute low-back pain <6 weeks, with/without radiculopathy; systematic review and GRADE (Skelly 2026, PMID 42687437); publisher record, accessed 2026-09-30 | Published 2026-09-02, accepted manuscript. Scope verified; detailed recommendations not extracted. AAPM's guideline hub, accessed 2026-09-30, still says “Coming Soon”; this site lag does not negate the publication. |
| ASIPP 2026 analytical summary of its 2025 regenerative guidance | Reports intradiscal PRP/BMAC Level III/fair evidence and moderate consensus recommendations (Manchikanti 2026, PMID 42804305) | Companion summary; retain the 2019 → 2025 supersession chain. Not a separate replacement guideline or new efficacy trial. |
The registry now contains 18 guideline/policy documents, plus the ASIPP companion summary. Official-site checks retained the existing WHO 2023, NICE NG59 (recorded then as last updated 2020; stale, see the 2026-10-14 correction below), VA/DoD 2022 and NASS low-back-pain listings; the KCE general-practice index still links its 2017 reports. No replacement was identified on those checked pages. This is a dated, source-limited result, not a declaration that every society worldwide has been exhaustively checked. Sources: WHO, NICE, VA/DoD, NASS, KCE, all accessed 2026-09-30.
Next (as written 2026-09-30): extract the complete acute-guideline recommendations and reconcile the AAPM hub; keep VA/DoD and KCE replacements on watch. The 2026-08-27 Chinese multidisciplinary consensus was discovered just outside this sweep's publication cutoff and is queued for the next targeted guideline check rather than silently counted as a September update.
2026-10-14 sweep¶
| Document/update | Verified scope and contribution | Status and limit |
|---|---|---|
| Correction: NICE NG59 July 2026 amendment | The NICE page reads "Last updated: 29 July 2026". NICE "withdrew the recommendations on psychological therapy for low back pain with or without sciatica, and combined physical and psychological programmes" (former 1.2.13, 1.2.14) and removed psychological-therapy references from 1.1.3 and 1.2.7. The reason given is that a surveillance review found them possibly out of date but an update was "not prioritised". Invasive recommendations 1.3.1, 1.3.9 and 1.3.10 are unchanged (update information, accessed 2026-10-14). | This registry's earlier "last updated 2020" status was stale by the 2026-08-30 and 2026-09-30 checks; corrected here. A withdrawal leaves NG59 silent on psychological care, not opposed to it. |
| Chinese multidisciplinary consensus (CSSLS/CAS), Bone Research 2026 | It drew on 653 of 4,703 retrieved publications, with literature to December 2025, and grades recommendations strong or weak, for or against (Gao 2026, PMID 42660880). From the full text: fusion is weak-for selected chronic discogenic pain when "symptoms and imaging are concordant" (Level I, Grade B). TDR is weak-for (Level I/II, Grade B). Intradiscal glucocorticoid is weak-for, with active discopathy/Modic change (Level I, Grade B). Intradiscal MSC is weak-for as investigational (Level I, Grade C). IDET and intradiscal radiofrequency thermocoagulation are research/audit/governance only. | The PRP recommendation is internally inconsistent: the boxed statement names ankylosing spondylitis–related pain, while the body text names chronic discogenic pain. The full text never mentions basivertebral/intraosseous ablation or vertebrogenic pain. Fusion/TDR directions contradict NICE 1.3.9–1.3.10. |
| AAPM acute guideline: hub reconciliation | The hub no longer says “Coming Soon”. It links a dedicated guideline page and a clinician key-recommendation summary covering imaging restraint, stepwise self-care, 1–2-week escalation options, radiculopathy-only systemic/epidural steroids (low certainty) and no routine opioids as initial treatment (AAPM, accessed 2026-10-14). | These are the society's summary bullets; full-guideline grades are still not extracted. Acute (<6 weeks) scope; not DDD-specific. |
The registry now contains 19 guideline/policy documents, plus the ASIPP companion summary. AAPM, NICE and BackCare sites returned HTTP 200 on 2026-10-14. VA/DoD, NASS, KCE and WHO were not re-checked this sweep; their statuses are as of 2026-09-30.
Next: extract the acute guideline's graded recommendations from the full text; check whether the NICE prioritisation decision is followed by any replacement psychological-care recommendation; watch for a correction to the Chinese consensus PRP statement; keep VA/DoD and KCE replacements on watch.
Per-guideline entries¶
WHO 2023¶
- Population: adults, including older adults, with chronic primary low-back pain in primary and community care.
- Excludes: surgery and other interventions normally delivered in secondary/tertiary care; workplace interventions.
- Contribution: global, discipline-neutral package emphasizing person-centered, coordinated combinations rather than single isolated modalities.
- Supported directions: education/self-care, exercise, selected physical and psychological therapies, NSAIDs in appropriate contexts.
- Against routine use: includes braces/belts, traction and opioids for most people in most contexts.
- Evidence companion: coordinated review series (Cancelliere 2023, PMID 37991650; Verville 2023, PMID 37991647; Southerst 2023, PMID 37991651).
- DDD boundary: does not validate an imaging-defined disc pain source.
NICE NG59 (2016; pharmacological sciatica update 2020)¶
- Population: low-back pain with or without sciatica in people aged 16 and older.
- Imaging: do not routinely image in non-specialist care; consider specialist imaging only if likely to change management.
- Noninvasive care: tailored self-management, normal activity and group exercise; manual therapy only "as part of a treatment package that includes exercise" (1.2.7, amended 2026). The psychological-therapy (1.2.13) and combined physical-psychological programme (1.2.14) recommendations were withdrawn in July 2026.
- Against: traction, acupuncture, several electrotherapies, spinal injections for low-back pain, chronic opioids and gabapentinoids for low-back pain.
- Invasive: epidural local anesthetic/steroid may be considered for acute severe sciatica; fusion only in an RCT for low-back pain; do not offer disc replacement for low-back pain.
- Status: official page says published 30 November 2016, last updated 29 July 2026 (accessed 2026-10-14). The earlier "11 December 2020" entry is superseded.
VA/DoD 2022¶
- Population: adults with low-back pain in VA/DoD systems.
- Structure: initial evaluation and management algorithms plus 39 evidence-based recommendations.
- Contribution: integrated diagnostic, nonpharmacologic, pharmacologic and systems guidance, with patient tools.
- Status: the official hub was last updated in 2025 and the central guideline index in 2026 states the lower-back-pain CPG is being updated.
- Watch: replacement version and changes to pharmacology/intervention recommendations.
NASS 2021 low-back-pain guideline¶
- Scope: a defined subset of adult low-back pain; the guideline explicitly excludes some neurological deficit and below-knee leg-pain presentations.
- Domains: diagnosis, imaging, medical/psychological, physical medicine/rehabilitation, interventional, surgical and cost-utility.
- Contribution: spine-specialty evidence grading across the care continuum.
- Boundary: recommendations should not be generalized to excluded radicular/neurological populations.
Australian Low Back Pain Clinical Care Standard 2022¶
- Population: patients aged ≥16 with a new acute episode, with or without leg pain.
- Eight statements: assessment, psychosocial factors, imaging stewardship, education, activity, medicines, review and referral.
- System feature: includes 11 implementation indicators.
- Boundary: explicitly excludes ongoing chronic-pain management, surgery indications and specific degenerative disorders.
- Contribution: unusually strong implementation, consumer and equity framing.
ACOEM 2020¶
- Population: working-age adults with acute, subacute and chronic low-back disorders.
- Evidence base: abbreviated publication reports 121 recommendations from a larger 862-page guideline; evidence sought across DDD, radiculopathy, spondylolisthesis, facet disease, failed surgery and stenosis.
- Contribution: work-disability, auditability and return-to-function perspective.
- Access caveat: full guideline is tied to MDGuidelines; the official ACOEM PDF is an abbreviated peer-reviewed summary.
Belgian KCE 2017 and pathway¶
- Scope: acute/chronic low-back and radicular pain with multidisciplinary input.
- Direction: demedicalization, continued movement, selective imaging and early risk stratification.
- Status: KCE explicitly warns its 2017 care-pathway guideline may be obsolete after five years.
- Update: KCE’s live project page states an update is planned in 2026 because the underlying literature review is approaching ten years old.
- Supersession chain: KCE 2017 remains the available base → KCE update project 2026 (not yet a replacement).
Danish Health Authority 2016¶
- Scope: treatment of recent-onset low-back pain.
- Contribution: national quick guide with evidence-based conservative-care recommendations.
- Status limitation: live source resolves, but a clear current/superseded declaration was not found in this session; treat as historical pending confirmation.
German NVL Kreuzschmerz v2 (2017)¶
- Scope: coordinated cross-sector care for nonspecific low-back pain.
- Status: official AWMF page states valid through 30 December 2021; it is expired.
- Use: historical comparison only; do not call current.
- Watch: replacement/re-registration in AWMF.
ACP 2017 and ACP/APS 2007¶
- ACP 2017: noninvasive acute/subacute/chronic nonradicular low-back pain; nonpharmacologic chronic care first, then selective medicines (PMID 28192789).
- ACP status: the official ACP registry now places it under inactive guidelines.
- ACP/APS 2007: broader diagnosis/treatment document; ACP says the 2017 guideline is a partial update.
- Chain: ACP/APS 2007 → partially superseded by ACP 2017 → ACP 2017 now inactive, with no replacement identified on the live ACP page.
NASS 2012 disc herniation with radiculopathy¶
- Scope: disc herniation with radiculopathy, not axial DDD.
- Contribution: preserves the critical boundary between root disease and structural degeneration.
- Status: still listed among completed NASS guidelines but is older than ten years; check for update before use.
ASIPP regenerative guidance 2019 → 2025¶
- 2019 contribution: responsible, safe and effective biologic use; evidence and governance framing (PMID 30717500).
- 2025 contribution: updated evidence-based recommendations for regenerative therapies (PMID 41481869).
- Chain: ASIPP 2019 → updated/superseded by ASIPP 2025.
- Conflict boundary: interventional-society grading may be more permissive than general low-back-pain guidelines; product-specific randomized evidence remains limited.
ASPN interventional guideline 2022¶
- Scope: evidence-based assessment of established and emerging interventional treatments across low-back-pain phenotypes (Sayed 2022, PMID 36510616).
- Contribution: places procedure-specific selection, effectiveness and safety in one interventional pathway.
- Boundary: a procedure guideline does not validate imaging-defined DDD as a uniform diagnosis; radicular, facet, sacroiliac, vertebrogenic and discogenic evidence must remain separated.
- Conflict: its eligible procedures and evidentiary thresholds are broader than NICE’s recommendation against spinal injections for nonspecific low-back pain.
- Status limitation: the peer-reviewed document resolved in the live PubMed sweep; an official current/superseded declaration was not established, so no stronger currency claim is made.
AANS/CNS fusion-guideline update 2014¶
- Injection/selection chapter: medial-branch ablation was suggested for 3–6 months of relief in selected nonradicular facet-mediated pain, while diagnostic medial-branch blocks were not supported as predictors of lumbar-fusion outcome (Watters 2014, PMID 24980590).
- Economic chapter: requires preference-based quality-of-life measurement such as EQ-5D to translate cost and outcomes into QALYs; an eight-year analysis informed its historical economic comparison (Ghogawala 2014, PMID 24980580).
- Boundary: neither chapter establishes a reliable painful-disc test or a generic fusion indication for an MRI degeneration label.
- Status: retained as historical guidance because a live supersession chain was not verified in this session.
Agreements¶
| Topic | Broad agreement |
|---|---|
| DDD label | Imaging degeneration alone does not define treatment |
| Assessment | Screen for serious pathology and neurological deficit |
| Imaging | Avoid routine early imaging when uncomplicated |
| Education | Explain, reassure and support self-management |
| Activity | Continue/restore normal activity |
| Exercise | Structured exercise for persistent pain |
| Opioids | Avoid routine long-term use |
| Radiculopathy | Separate from axial pain |
| Surgery | Requires selected phenotype and concordance |
| Biologics | Evidence/product governance is essential |
Disagreements and gaps¶
| Topic | Guideline disagreement | Evidence gap |
|---|---|---|
| Acupuncture | ACP includes as an option; NICE says do not offer | Context, comparator and cost effectiveness |
| Manual therapy | Offered alone or only in a package | Active ingredient and durability |
| Duloxetine | ACP second-line option; NICE says do not offer antidepressants for low-back pain | Small effect and phenotype selection |
| Spinal injections | NICE says do not offer for low-back pain; interventional bodies endorse selected procedures | Discogenic construct and sham evidence |
| Fusion | NICE limits to RCT for low-back pain; spine practice/guidance permits selected surgery | Valid level-selection and active comparator |
| Disc replacement | NICE says do not offer for low-back pain; device/spine evidence supports narrow DDD eligibility | Lifetime device-specific net benefit |
| Basivertebral ablation | Absent from older general guidelines | Independent replication and placement in pathway |
| Regenerative therapy | General guidelines largely omit; ASIPP offers evidence grading | Product standardization and late safety |
| Interventional pathway | ASPN/ASIPP evaluate selected procedures; NICE is substantially more restrictive for nonspecific axial pain | Independent sham replication, phenotype boundaries and opportunity cost |
| Fusion prediction | Historical AANS/CNS guidance rejects medial-branch blocks as fusion predictors; surgical selection still uses heterogeneous tests | Externally validated treatment-effect model |
| Imaging communication | Stewardship endorsed; wording rarely specified | Nocebo-reducing report trials |
| Work participation | Prominent in occupational guidance, less elsewhere | Cross-system implementation |
Watch list¶
| Body/document | Watch item | Next check |
|---|---|---|
| VA/DoD low-back-pain CPG | 2022 remains listed; verify replacement timing rather than infer an active update | 2026 Q4 |
| KCE Belgium | Planned 2026 update project | 2027 Q1 |
| ACP | Replacement for inactive 2017 guideline | 2027 Q1 |
| NICE NG59 | Any replacement for the withdrawn psychological-care recommendations; new evidence-triggered review | 2027 Q1 |
| NASS low-back pain | Revision/update status | 2027 Q1 |
| NASS disc herniation | Replacement for 2012 document | 2027 Q1 |
| ACOEM | Five-year comprehensive update | 2027 Q1 |
| German AWMF/NVL | Replacement for expired v2 | 2027 Q1 |
| Danish Health Authority | Current/superseded declaration | 2027 Q1 |
| ASIPP regenerative | New product-specific trials and safety updates | 2027 Q1 |
| WHO | Implementation tools and updates | 2027 Q1 |
| ASPN interventional guideline | Official revision or supersession statement | 2027 Q1 |
| AANS/CNS lumbar-fusion series | Current replacement/supersession chain | 2027 Q1 |
Sources checked¶
- World Health Organization — “WHO guideline for non-surgical management of chronic primary low back pain in adults in primary and community care settings,” https://www.who.int/publications/i/item/9789240081789, accessed 2026-08-30.
- NICE — “Low back pain and sciatica in over 16s: recommendations,” https://www.nice.org.uk/guidance/NG59/chapter/recommendations, accessed 2026-08-30 and 2026-10-14.
- NICE — “Low back pain and sciatica in over 16s: update information,” https://www.nice.org.uk/guidance/ng59/chapter/Update-information, accessed 2026-10-14.
- AAPM — “Acute Low Back Pain Guideline - Clinician Resources,” https://www.painmed.org/acute-low-back-pain-clinicians, accessed 2026-10-14.
- VA/DoD — “Diagnosis and Treatment of Low Back Pain (2022),” https://www.healthquality.va.gov/guidelines/pain/lbp/index.asp, accessed 2026-08-30.
- NASS — “Clinical Guidelines,” https://www.spine.org/Research/Clinical-Guidelines/Low-Back-Pain, accessed 2026-08-30.
- Australian Commission on Safety and Quality in Health Care — “Low Back Pain Clinical Care Standard,” https://www.safetyandquality.gov.au/clinical-care-standards/low-back-pain, accessed 2026-08-30.
- KCE — “Clinical guideline on low-back and radicular pain,” https://kce.fgov.be/nl/publicaties/alle-rapporten/klinische-richtlijn-rond-lage-rugpijn-en-radiculaire-pijn, accessed 2026-08-30.
- ACOEM — “Non-Invasive and Minimally Invasive Management of Low Back Disorders,” https://acoem.org/acoem/media/News-Library/Practice-Guidelines-Non_Invasive-Low-Back-Pain-March-2020-JOEM_1.pdf, accessed 2026-08-30.
- AWMF — “Nationale VersorgungsLeitlinie Kreuzschmerz,” https://www.awmf.org/aktuelles/awmf-aktuell/nationale-versorgungsleitlinie-kreuzschmerz-2, accessed 2026-08-30.
- Danish Health Authority — “National clinical guideline for recent-onset low back pain,” https://sundhedsstyrelsen.dk/da/udgivelser/2016/-/media/Udgivelser/2016/NKR-l%C3%A6nderygsmerter/EN_260736-NKR---L%C3%A6ndesmerter-quickguide-english.ashx, accessed 2026-08-30.
- ASIPP — “Regenerative Medicine Guidelines,” https://asipp.org/regenerative-medicine-guidelines/, accessed 2026-08-30.